Tedizolid phosphate is under clinical development by Merck and currently in Phase III for Abscess. According to GlobalData, Phase III drugs for Abscess have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tedizolid phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tedizolid phosphate overview

Tedizolid phosphate (TR-701, DA-7218, Sivextro) is a phosphate prodrug, is converted to tedizolid in the presence of phosphatases. It is formulated as injectable powder solution and concentrate solution for intravenous route of administration and tablets, coated tablets and film coated tablets for oral route of administration. Tedizolid phosphate is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), soft tissue infections (SSTI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, streptococcus agalactiae, streptococcus anginosus group (including streptococcus anginosus, streptococcus intermedius and streptococcus constellatus), and enterococccus faecalis.

The drug candidate is under development for the treatment of acute bacterial skin and skin structure infections including cellulitis, erysipelas, major cutaneous abscess, wound infection and gram-positive infections. It was also under development for the treatment of ventilator associated bacterial Pneumonia (VABP) and hospital acquired bacterial Pneumonia (HABP), cellulitis, erysipelas, bacteremia and and skin and soft tissue infections (SSTI),  complicated skin and skin structure infections and methicillin-resistant Staphylococcus aureus (MRSA) infections.

Merck overview

Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

For a complete picture of Tedizolid phosphate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.